ECM-receptor interaction was enriched based on the KEGG pathway in our study, while COL3A1, COL5A2, and COL2A1 were regarded as potential ECM components associated with cytostatic drug resistance in ovarian cancer cells [23]. Here, COL3A1 is linked to ovarian carcinoma.